Lauren Santye, Assistant Editor

Higher consumer out-of-pocket costs could be a barrier to patient adoption of biosimilar drugs.

Ocrevus is a humanized monoclonal antibody that targets CD20-positive B cells in MS patients.

HCV testing rises in substance use disorder treatment programs.

Raltegravir in long-acting formulation may only be needed every month in HIV patients.

Injections of new formulation of raltegravir may only be needed every month.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Ruptured cancerous cells are able to repair themselves to prevent cell death.

Zepatier boasts sustained virologic response rates of 99% in hepatitis C genotypes 1 and 4.

Top news of the day from across the health care landscape.

Work is still needed to achieve the significant promise of mobile health applications.

Specially synthesized plant peptide cyclotide found to suppress onset of multiple sclerosis.

Naloxone increases survival rates and reduced mortality rates from heroin overdoses.

Looming clinical trials offer hope for patients with Parkinson’s disease.

Study finds need for improved understanding of the association between rising systemic therapy use and the uptake of palliative care.

Inhibiting newly classified enzymes may lead to treatments for type 2 diabetes, inflammation, and autoimmune disease.

Top news of the day from across the health care landscape.

Inflectra biosimilar treats conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Inhibiting GCN5 enzyme may lead to reduced remission risks and improved cure rates.

Program leads to estimated Medicare savings of $2650 for each enrollee over a 15-month period.

Top news of the day from across the health care landscape.

While PSA levels decreased in patients, overall survival did not improve in patients with non-metastatic prostate cancer.

New system could lead to advances in cancer investigation and drug discovery.

Venclexta is designed to trigger a natural process that helps cells self-destruct in chronic lymphocytic leukemia (CLL).

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Findings on x-linked reticulate pigmentary disorder (XLPDR) could lead to new targeted therapies.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

Atezolizumab was previously granted Breakthrough Therapy Designation for NSCLC in February 2015.